Chimeric Therapeutics (ASX:CHM) FCF Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Chimeric Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Chimeric Therapeutics's Free Cash Flow for the six months ended in Dec. 2023 was A$-4.68 Mil. Chimeric Therapeutics's Revenue for the six months ended in Dec. 2023 was A$0.00 Mil. Therefore, Chimeric Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, Chimeric Therapeutics's current FCF Yield % is -63.60%.

The historical rank and industry rank for Chimeric Therapeutics's FCF Margin % or its related term are showing as below:

ASX:CHM's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -141.025
* Ranked among companies with meaningful FCF Margin % only.

Chimeric Therapeutics FCF Margin % Historical Data

The historical data trend for Chimeric Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimeric Therapeutics FCF Margin % Chart

Chimeric Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

FCF Margin %

Chimeric Therapeutics Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Chimeric Therapeutics's FCF Margin %

For the Biotechnology subindustry, Chimeric Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chimeric Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chimeric Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Chimeric Therapeutics's FCF Margin % falls into.

Chimeric Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Chimeric Therapeutics's FCF Margin for the fiscal year that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	-16.418	/	0
	=	%

Chimeric Therapeutics's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-4.681	/	0
	=	%

Chimeric Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Chimeric Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Chimeric Therapeutics (ASX:CHM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (ASX:CHM) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

CHMMF:USA

Address

62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053

Website

https://www.chimerictherapeutics.com

Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

Chimeric Therapeutics (ASX:CHM) Headlines

No Headlines